Skip to main content

Advertisement

Log in

Interstitial pneumonitis induced by pegylated liposomal doxorubicin in a patient with recurrent ovarian cancer

  • Case Report
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Interstitial pneumonitis after treatment with pegylated liposomal doxorubicin (PLD) has been rarely reported. We describe herein a case of interstitial pneumonitis in a 49-year-old woman with relapsed ovarian carcinoma treated with PLD. Twenty-five days after the second administration of PLD, she presented with fever and dry cough, and chest CT scans revealed bilateral interstitial infiltrates and ground-glass opacities. She was diagnosed to have interstitial pneumonitis induced by PLD. Steroid therapy improved her symptoms.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

References

  1. Gordon AN, et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol. 2001;19:3312–22.

    PubMed  CAS  Google Scholar 

  2. Gordon AN, et al. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol. 2004;95:1–8.

    Article  PubMed  CAS  Google Scholar 

  3. Ferrandina G, et al. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol. 2008;26:890–6.

    Article  PubMed  CAS  Google Scholar 

  4. Uziely B, et al. Liposomal doxorubicin: antitumor activity and unique toxicity during two complementary phase I studies. J Clin Oncol. 1995;13:1777–85.

    PubMed  CAS  Google Scholar 

  5. Thigpen JT, et al. Role of pegylated liposomal doxorubicin in ovarian cancer. Gynecol Oncol. 2005;96:10–8.

    Article  PubMed  CAS  Google Scholar 

  6. Huober J, Schoch O, Templeton A, Christian S, Thurlimann B. Interstitial pneumonitis after treatment with bevacizumab and pegylated liposomal doxorubicin in a patient with metastatic breast cancer. Chemotherapy. 2010;56:69–70.

    Article  PubMed  CAS  Google Scholar 

  7. Kim KM, et al. Rituximab-CHOP induced interstitial pneumonitis in patients with disseminated extranodal marginal zone B cell lymphoma. Yonsei Med J. 2008;49(1):155–8.

    Article  PubMed  Google Scholar 

  8. Satoh H, Kurishima K, Ishikawa H, Ohtsuka M. Increased levels of KL-6 and subsequent mortality in patients with interstitial lung diseases. J Intern Med. 2006;260:429–34.

    Article  PubMed  CAS  Google Scholar 

  9. Cohen MH, Williams GA, Sridhara R, Chan G, Pazdur R. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist. 2003;8(4):303–6.

    Article  PubMed  CAS  Google Scholar 

  10. Takeishi M, et al. Leflunomide induced acute interstitial pneumonia. J Rheumatol. 2005;32(6):1160–3.

    PubMed  Google Scholar 

Download references

Conflict of interest

No author has any conflict of interest.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Takahide Arimoto.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Inaba, K., Arimoto, T., Hoya, M. et al. Interstitial pneumonitis induced by pegylated liposomal doxorubicin in a patient with recurrent ovarian cancer. Med Oncol 29, 1255–1257 (2012). https://doi.org/10.1007/s12032-011-9893-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-011-9893-0

Keywords

Navigation